Long-term safety of spironolactone in acne: Results of an 8-year followup study

被引:68
作者
Shaw, JC
White, LE
机构
[1] Univ Toronto, Toronto Western Hosp, Div Dermatol, Toronto, ON M5T 2S8, Canada
[2] Macneal Mem Hosp, Dept Med, Berwyn, IL USA
关键词
D O I
10.1007/s10227-001-0152-4
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Spironolactone has been used for over 20 years as an antiandrogen in the treatment of acne and hirsutism. No long-term studies of the safety of spironolactone used in this manner have been published. We present a study of the long-term safety and tolerance of spironolactone in 91 women with acne who were followed for up to 8 years. Methods. A survey questionnaire was sent to 210 patients, and a comparison chart review of all patients to whom the survey was sent was made. Results. Ninety-one completed surveys were analyzed, comprising 506 person-years of followup and 200 person-years of spironolactone exposure. Mean treatment length was 28.5 months (range = 0.5--122 months). During the 8-year followup period, there were no cases of serious illness attributable to spironolactone use. Side effects were present in 59% and resulted in cessation of the drug in 15%. Diuretic effect and menstrual irregularities were the most common adverse effects. Conclusions: After 200 person-years of exposure to spironolactone and 506 person-years of followup over 8 years, no serious illnesses thought to be attributed to spironolactone were reported. The long-term use of spironolactone in the treatment of acne in women appears to be safe. Side effects, however, are common, although not usually a cause for stopping the drug.
引用
收藏
页码:541 / 545
页数:5
相关论文
共 10 条
[1]  
BARKER DJP, 1987, J DRUG DEV S2, V1, P22
[2]   NON-ESTROGENIC DRUGS AND BREAST-CANCER [J].
DANIELSON, DA ;
JICK, H ;
HUNTER, JR ;
STERGACHIS, A ;
MADSEN, S .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1982, 116 (02) :329-332
[3]   INITIAL SCREENING FOR CARCINOGENICITY OF COMMONLY USED DRUGS [J].
FRIEDMAN, GD ;
URY, HK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1980, 65 (04) :723-733
[4]   ORAL SPIRONOLACTONE IMPROVES ACNE-VULGARIS AND REDUCES SEBUM EXCRETION [J].
GOODFELLOW, A ;
ALAGHBANDZADEH, J ;
CARTER, G ;
CREAM, JJ ;
HOLLAND, S ;
SCULLY, J ;
WISE, P .
BRITISH JOURNAL OF DERMATOLOGY, 1984, 111 (02) :209-214
[5]   TOLERANCE OF SPIRONOLACTONE [J].
HUGHES, BR ;
CUNLIFFE, WJ .
BRITISH JOURNAL OF DERMATOLOGY, 1988, 118 (05) :687-691
[6]  
LEE O, 2000, COCHRANE DB SYST REV, P194
[7]   BREAST-CANCER ASSOCIATED WITH ADMINISTRATION OF SPIRONOLACTONE [J].
LOUBE, SD ;
QUIRK, RA .
LANCET, 1975, 1 (7922) :1428-1429
[8]   Low-dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients [J].
Shaw, JC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (03) :498-502
[9]   SPIRONOLACTONE IN DERMATOLOGICAL THERAPY [J].
SHAW, JC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (02) :236-243
[10]   The human sebocyte culture model provides new insights into development and management of seborrhoea and acne [J].
Zouboulis, CC ;
Xia, L ;
Akamatsu, H ;
Seltmann, H ;
Fritsch, M ;
Hornemann, S ;
Rühl, R ;
Chen, W ;
Nau, H ;
Orfanos, CE .
DERMATOLOGY, 1998, 196 (01) :21-31